QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug Lakin who started this subject	11/25/2003 9:25:20 AM
From: Doc Bones	Read Replies (1) of 1321

09:17 QLTI started with an Overweight at ThinkEquity (16.41 ) ThinkEquity initiates coverage of QLT Inc with an Overweight rating and $20-$21 target range; firm believes that the potential of Visudyne (partnered 50/50 with Novartis) is under-recognized and is poised for near-term growth, driven by: 1) an expected positive CMS decision on reimbursement for occult AMD by year-end 2003, 2) the streamlining of the relationship with Novartis Ophthalmics, which is beginning to deliver, 3) geographic expansion, and 4) a compelling potential for combination therapy. [briefing.com]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next